CRISPR Therapeutics (NASDAQ:CRSP) Stock Price Down 0.2%

CRISPR Therapeutics AG (NASDAQ:CRSP - Get Free Report) shares fell 0.2% during trading on Thursday . The company traded as low as $61.32 and last traded at $61.63. 265,443 shares traded hands during trading, a decline of 86% from the average session volume of 1,868,561 shares. The stock had previously closed at $61.74.

Analyst Ratings Changes

A number of brokerages have commented on CRSP. Morgan Stanley raised their price target on shares of CRISPR Therapeutics from $46.00 to $48.00 and gave the stock an "underweight" rating in a research note on Monday, February 26th. Barclays raised their price target on shares of CRISPR Therapeutics from $61.00 to $80.00 and gave the stock an "equal weight" rating in a research note on Thursday, February 22nd. Chardan Capital raised their price objective on shares of CRISPR Therapeutics from $110.00 to $112.00 and gave the stock a "buy" rating in a report on Thursday, February 22nd. Wolfe Research began coverage on shares of CRISPR Therapeutics in a report on Thursday, February 15th. They set a "peer perform" rating for the company. Finally, TheStreet raised shares of CRISPR Therapeutics from a "d+" rating to a "c" rating in a report on Friday, February 23rd. Three investment analysts have rated the stock with a sell rating, six have issued a hold rating and nine have given a buy rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus target price of $74.75.

CRISPR Therapeutics Price Performance

The business's 50-day moving average price is $74.09 and its two-hundred day moving average price is $62.88. The company has a market capitalization of $5.05 billion, a P/E ratio of -32.10 and a beta of 1.76.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last posted its quarterly earnings data on Wednesday, February 21st. The company reported $1.10 EPS for the quarter, beating the consensus estimate of $0.15 by $0.95. The company had revenue of $201.20 million during the quarter, compared to the consensus estimate of $148.72 million. During the same period in the prior year, the firm posted ($1.41) earnings per share. The company's revenue was up 3253.3% compared to the same quarter last year. Research analysts expect that CRISPR Therapeutics AG will post -6.24 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other CRISPR Therapeutics news, General Counsel James R. Kasinger sold 1,913 shares of the business's stock in a transaction dated Tuesday, February 20th. The shares were sold at an average price of $79.67, for a total transaction of $152,408.71. Following the sale, the general counsel now directly owns 57,371 shares of the company's stock, valued at approximately $4,570,747.57. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In related news, CEO Samarth Kulkarni sold 50,000 shares of the company's stock in a transaction dated Monday, January 29th. The shares were sold at an average price of $60.51, for a total value of $3,025,500.00. Following the transaction, the chief executive officer now owns 187,377 shares in the company, valued at approximately $11,338,182.27. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, General Counsel James R. Kasinger sold 1,913 shares of the stock in a transaction that occurred on Tuesday, February 20th. The stock was sold at an average price of $79.67, for a total transaction of $152,408.71. Following the transaction, the general counsel now owns 57,371 shares in the company, valued at approximately $4,570,747.57. The disclosure for this sale can be found here. Insiders have sold 134,410 shares of company stock valued at $9,234,677 in the last three months. 4.10% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in CRSP. Fairfield Bush & CO. acquired a new position in shares of CRISPR Therapeutics during the 1st quarter worth approximately $90,000. Bank of New York Mellon Corp lifted its holdings in shares of CRISPR Therapeutics by 40.7% during the 1st quarter. Bank of New York Mellon Corp now owns 91,062 shares of the company's stock worth $5,716,000 after acquiring an additional 26,358 shares during the period. US Bancorp DE lifted its holdings in shares of CRISPR Therapeutics by 10.0% during the 1st quarter. US Bancorp DE now owns 9,526 shares of the company's stock worth $598,000 after acquiring an additional 866 shares during the period. BlackRock Inc. lifted its holdings in shares of CRISPR Therapeutics by 79.2% during the 1st quarter. BlackRock Inc. now owns 2,278,774 shares of the company's stock worth $143,038,000 after acquiring an additional 1,007,246 shares during the period. Finally, Cibc World Market Inc. lifted its holdings in shares of CRISPR Therapeutics by 49.3% during the 1st quarter. Cibc World Market Inc. now owns 8,354 shares of the company's stock worth $524,000 after acquiring an additional 2,760 shares during the period. Institutional investors and hedge funds own 69.20% of the company's stock.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.